# Intermediate-dose HAD Regimen for CEBPA Double-mutated AML

> **NCT06529250** · NA · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 148 (estimated)

## Conditions studied

- AML

## Interventions

- **DRUG:** HAD
- **DRUG:** Daunorubicin+Cytarabine

## Key facts

- **NCT ID:** NCT06529250
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-13
- **Primary completion:** 2026-08-30
- **Final completion:** 2028-09-01
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06529250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06529250, "Intermediate-dose HAD Regimen for CEBPA Double-mutated AML". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06529250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*